Archive: Company News
Omnix Medical Receives NIH Grant for the Development of its Novel Antimicrobial Peptide OMN6
— Funding supports unique approach for fighting multi-drug resistant Acinetobacter baumannii (AB)
— Clinical trial preparations of OMN6 under way
Omnix Medical, a Jerusalem-based biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, has received a grant by the U.S. National Institutes of Health (NIH) for the development of its first-in-class antimicrobial peptide OMN6 targeting Acinetobacter baumannii (AB). Acinetobacter baumannii are multi-drug resistant (MDR) bacteria and designated number one on the WHO/CDC Global Priority Pathogens List.
T-knife Therapeutics Appoints Peggy Sotiropoulou, Ph.D. as Chief Scientific Officer
T-knife Therapeutics, Inc. a next-generation T-cell receptor company developing a pipeline of innovative therapeutics for patients with solid tumors, today announced the appointment of cell therapy and immuno-oncology thought leader, Peggy Sotiropoulou, Ph.D., as its Chief Scientific Officer.
Neonatal Diagnostics Company InfanDx AG Appoints Dr. Gunter Weiss as COO
— Dr. Weiss brings more than 15 years of experience in biomarker and in vitro diagnostics development
— Company launched targeted recruiting campaign for next phase of corporate life cycle
InfanDx AG (Cologne, Germany), a privately held diagnostics company focusing on the development and commercialization of novel diagnostic solutions for newborns, today announced the appointment of Dr. Gunter Weiss as Chief Operating Officer (COO). In this role, Dr. Weiss will be in charge of the further clinical development of InfanDx’ biomarkers for Hypoxic Ischemic Encephalopathy (HIE) and the further development of HypoxE® IVD tests detecting such biomarkers in blood samples from newborns. Such tests will be developed for use on various diagnostic instrument platforms suited for diagnostic laboratories and point-of-care settings, e.g. delivery rooms.
T-knife Therapeutics Announces $110 Million Series B Financing to Advance Pipeline of T-cell Receptor Therapies
— Plan to initiate the IMAG1NE Phase 1/2 clinical study of TK-8001, a TCR-T cell therapy for MAGE-A1 positive solid tumors, in 2021
T-knife Therapeutics, Inc., a next-generation T-cell receptor company developing a pipeline of innovative therapeutics for solid tumor patients, today announced the successful completion of a $110 million Series B financing. The financing was led by Fidelity Management & Research Company, LLC., with participation from other new investors including, LSP, Qatar Investment Authority (QIA), Casdin Capital, Sixty Degree Capital, and CaaS Capital, along with existing investors RA Capital Management, Versant Ventures and founding investor Andera Partners. Read more…